Doctor-Supervised GIP/GLP-1 Weight Management in Singapore
Weight management is not simply a matter of willpower. Appetite, metabolic health, sleep, stress, medical conditions and genetics can all influence how easily someone gains or loses weight.
For suitable patients, doctor-prescribed GIP/GLP-1 weight management injections may be used alongside nutrition, exercise and behavioural changes. These medications influence the gut–brain pathways involved in appetite and fullness, helping some patients feel satisfied with smaller portions.
At Emberwood Aesthetics, treatment begins with a medical assessment and is prescribed only when clinically appropriate. The aim is not just to achieve a lower number on the scale, but to support sustainable fat loss while protecting muscle mass, nutrition and overall health.
Looking for weight loss treatment in Singapore?
Weight management is not simply a matter of willpower. Appetite, metabolic health, sleep, stress, medical conditions and genetics can all influence how easily someone gains or loses weight.
For suitable patients, doctor-prescribed GIP/GLP-1 weight management injections may be used alongside nutrition, exercise and behavioural changes. These medications influence the gut–brain pathways involved in appetite and fullness, helping some patients feel satisfied with smaller portions.
At Emberwood Aesthetics, treatment begins with a medical assessment and is prescribed only when clinically appropriate. The aim is not just to achieve a lower number on the scale, but to support sustainable fat loss while protecting muscle mass, nutrition and overall health.
What Are GIP and GLP-1, and How Do They Support Weight Management?
GIP and GLP-1 are naturally occurring gut hormones released after eating. They help regulate appetite, food intake and blood sugar.
GLP-1 plays several roles that are relevant to weight management. It can:
Increase feelings of fullness
Reduce appetite and calorie intake
Slow stomach emptying, particularly when treatment is first started
Stimulate insulin release when blood glucose is elevated
Reduce glucagon secretion
GIP is another gut-derived hormone involved in insulin response and the regulation of food intake and metabolism.
Some weight-management medications act on the GLP-1 receptor alone, while newer dual-action medications activate both the GIP and GLP-1 receptors. These medications are designed to influence appetite and calorie intake as part of a medically supervised weight-management programme.
How Do GIP/GLP-1 Weight Management Injections Work?
GIP/GLP-1 weight-management medications work by activating hormone pathways involved in appetite, food intake and blood sugar regulation.
By influencing appetite signals in the brain and, particularly when treatment is first started, slowing stomach emptying, they may help you:
Feel full sooner during meals
Stay satisfied for longer
Experience less hunger between meals
Reduce cravings and unnecessary snacking
Find it easier to eat smaller portions
These medications do not directly melt or remove body fat. Their effect on body weight is primarily related to reducing appetite and calorie intake over time. Current prescribing information for dual GIP/GLP-1 therapy specifically notes that reduced calorie intake is likely mediated through effects on appetite.
Medication Is Only One Part of Weight Management
GIP/GLP-1 treatment is intended to be used as part of a broader weight-management plan rather than as a stand-alone solution.
Depending on your individual needs, this may include an appropriate eating plan, regular physical activity and resistance exercise, adequate protein intake, sleep and ongoing medical review. Weight-management medications themselves are indicated alongside a reduced-calorie diet and increased physical activity.
What Is “GLP-1 Face”?
“GLP-1 face” is an informal term used to describe facial changes that may become noticeable after substantial or rapid weight loss.
Possible changes include:
Reduced cheek or temple volume
More prominent facial folds
Looser-looking skin
A hollow or tired appearance
Increased visibility of the jawline or bony contours
These changes are not a unique toxic effect of GLP-1 medication. They can occur after significant weight loss through medication, dieting, bariatric surgery or other methods.
The face naturally contains superficial and deep fat compartments. When overall body fat decreases, facial volume may decrease as well. Skin may also take time to adapt to the change in underlying volume.
Can “GLP-1 Face” Be Prevented?
It cannot always be prevented, and protein cannot selectively preserve facial fat. However, several measures may support a healthier-looking result:
Avoid trying to lose weight faster than medically necessary
Follow gradual dose escalation rather than increasing the dose prematurely
Eat sufficient protein and nutrient-dense foods
Perform regular resistance exercise
Stay adequately hydrated
Avoid smoking
Use daily sunscreen
Allow time for the face and skin to adjust after weight stabilises
If facial changes remain bothersome after weight has stabilised, a separate facial assessment can consider options such as skin-tightening treatments, collagen-stimulating procedures or carefully placed volume replacement. Treatment should remain conservative and proportionate to the degree of volume loss.
Why Is Protein Important During GIP/GLP-1 Treatment?
When body weight decreases, the weight lost is not exclusively fat. Some lean tissue, including muscle, may also be lost.
Because GIP/GLP-1 medications can significantly reduce appetite, patients may unintentionally eat too little protein or skip meals. This can contribute to:
Loss of strength
Reduced muscle mass
Fatigue
Lower physical function
A less favourable change in body composition
Difficulty maintaining weight loss over time
The goal should therefore be fat loss with maximum practical preservation of muscle, rather than simply making body weight fall as quickly as possible.
How Much Protein Should I Eat?
Protein requirements should be individualised according to your body composition, age, activity level, medical history and kidney function.
During active weight loss, a commonly used clinical range is approximately 1.2 to 1.6 grams of protein per kilogram per day, calculated using an appropriate actual, ideal or adjusted body weight.
This range is not suitable for everyone. Patients with kidney disease, certain liver conditions or other medical concerns require individual dietary advice.
Rather than consuming all your protein at dinner, try to distribute it across the day.
Protein-rich choices include:
Eggs
Fish and seafood
Chicken or lean meat
Greek yoghurt or cottage cheese
Milk or fortified soy milk
Tofu, tempeh and edamame
Lentils, chickpeas and beans
Protein shakes when whole-food intake is insufficient
When appetite is low, it may help to eat the protein portion of the meal first.
Is a High-Protein Diet Enough to Prevent Muscle Loss?
No. Protein intake and resistance exercise work together.
A suitable programme may include resistance training two to three times a week, using:
Weights
Resistance bands
Body-weight exercises
Pilates-based resistance exercises
Supervised strength training
Walking and cardiovascular exercise remain beneficial for heart health and energy expenditure, but they do not fully replace resistance training for preserving muscle.
What Should I Eat While Taking GIP/GLP-1 Medication?
A healthy weight-management diet should still be balanced, even when portions become smaller.
Prioritise:
High-quality protein at each meal
Vegetables and whole fruits
Fibre-rich carbohydrates in appropriate portions
Healthy fats
Adequate fluid intake
Small, regular meals if large portions cause nausea
Nutrient-dense foods rather than relying on very low-calorie snacks
Try to limit:
Very large meals
Heavy, greasy or high-fat meals
Excessive alcohol
Sugary drinks
Eating rapidly
Lying down immediately after eating
Continuing to eat after comfortably full
Eating too little is not necessarily better. Persistent inability to meet basic nutritional requirements may mean the dose is too strong or that the treatment plan needs adjustment.
What Are the Common Side Effects?
The most common side effects affect the digestive system, particularly when treatment is started or the dose is increased.
These may include:
Nausea
Reduced appetite
Bloating
Reflux or indigestion
Constipation
Diarrhoea
Vomiting
Abdominal discomfort
Side effects are often mild to moderate and may improve as the body adjusts. Starting with a lower dose and increasing it gradually can improve tolerability.
Do not increase the dose simply because weight loss has slowed. Dose changes should be based on response, side effects, nutritional intake and medical assessment.
Who May Be Suitable for Medical Weight Management?
In Singapore, approved weight-management indications generally include adults with:
A body mass index of 30 kg/m² or above; or
A body mass index of 27 kg/m² or above with at least one weight-related medical condition
Relevant conditions may include:
Prediabetes or type 2 diabetes
High blood pressure
High cholesterol
Obstructive sleep apnea
Cardiovascular disease
BMI is a useful screening measurement, but it does not provide a complete picture of health. Waist circumference, body composition, medical history, medications and previous weight-loss attempts should also be considered.
These injections are prescription medicines and are not suitable for everyone.
How Does Dual GIP/GLP-1 Therapy Compare With GLP-1 Therapy?
Both options are commonly administered once weekly and are intended to be used with a reduced-calorie diet and increased physical activity.
Dual GIP/GLP-1 receptor agonist
A dual-action medication activates both GIP and GLP-1 receptors.
Potential characteristics include:
Action through two complementary gut-hormone pathways
Reduction in appetite and calorie intake
Once-weekly administration
Gradual dose escalation to improve tolerability
Greater average weight reduction than the GLP-1-only option in one direct clinical trial
GLP-1 receptor agonist
A GLP-1 receptor agonist acts primarily through the GLP-1 pathway.
Potential characteristics include:
Reduction in appetite and increased satiety
Once-weekly administration
Gradual dose escalation
Extensive clinical experience in diabetes and weight management
Cardiovascular-outcomes evidence for certain patients with established cardiovascular disease
Which Option Produces More Weight Loss?
In a 72-week head-to-head clinical trial involving adults with obesity or overweight and a related health condition, but without diabetes, the dual GIP/GLP-1 medication produced a greater average reduction in body weight than the GLP-1-only medication.
Average weight reduction was approximately:
20.2% with the dual GIP/GLP-1 medication
13.7% with the GLP-1-only medication
These figures are study averages, not guaranteed individual results. Participants were treated with the maximum tolerated doses alongside lifestyle intervention.
Results in daily clinical practice may differ because of dose tolerance, adherence, medical conditions, eating patterns, physical activity and duration of treatment.
Does That Mean Dual GIP/GLP-1 Is Always Better?
No. Greater average weight loss does not automatically make one medication the best choice for every patient.
The appropriate option depends on:
Your starting BMI and treatment goal
Presence of diabetes or cardiovascular disease
Previous response to weight-management medication
Gastrointestinal sensitivity
Other medications
Pregnancy plans and contraception
Cost and medication availability
The amount of weight loss that would be clinically appropriate
Your ability to maintain adequate nutrition and muscle mass
Some patients respond very well to GLP-1-only therapy, while others may benefit from a dual GIP/GLP-1 approach. Treatment should be selected and adjusted by a doctor rather than chosen solely based on headline weight-loss percentages.
What Does a Doctor-Supervised Programme Involve?
Medical weight management should involve more than dispensing an injection.
A programme may include:
Medical and weight history
Review of previous weight-loss attempts
BMI and waist measurement
Body-composition assessment where appropriate
Blood pressure measurement
Review of current medication and supplements
Baseline blood tests where clinically indicated
Discussion of pregnancy plans and contraception
Nutrition and protein planning
Exercise recommendations
Gradual dose adjustment
Monitoring of side effects and progress
A long-term maintenance plan
The highest available dose is not automatically the most appropriate dose. The objective is to find the lowest effective and tolerable dose that supports clinically meaningful progress.
Frequently Asked Questions about GIP/GLP-1 Weight Management
-
No. They are not insulin. They act on gut-hormone receptors involved in appetite, digestion and glucose-dependent insulin release.
-
The commonly used dual GIP/GLP-1 and GLP-1 options are administered once weekly. They should be used only according to the prescribed instructions.
-
It is administered under the skin, commonly in the abdomen, thigh or upper arm. Injection sites should be rotated.
-
Some patients notice appetite changes soon after starting, while others respond only after gradual dose escalation. An immediate dramatic appetite reduction is not necessary for the treatment to be working.
-
No. Clinical-trial percentages are averages across groups of participants. Individual outcomes vary, and the appropriate goal depends on your health, starting weight, response and treatment duration.
Even a more modest reduction in body weight may improve blood pressure, blood glucose, mobility and other health markers.
-
Appetite may return after stopping, and some weight regain is common without an effective maintenance plan. Obesity is often a chronic and relapsing condition, so the duration of treatment should be discussed individually.
Medication should not be stopped or restarted without medical guidance.
-
Alcohol may worsen nausea, reflux or dehydration and can add significant calories. It may also be unsuitable for patients with pancreatitis risk, liver disease, high triglycerides or poorly controlled diabetes.
Discuss your alcohol intake with your doctor.
-
The risk is generally low when used by itself because its insulin effects are glucose-dependent. The risk increases when it is combined with insulin or certain diabetes medications.
-
It may help to:
Eat smaller portions
Stop eating when comfortably satisfied
Avoid greasy or very rich foods
Eat slowly
Maintain fluid intake
Avoid lying down immediately after meals
Avoid increasing the dose until symptoms have settled
Persistent or severe nausea should be medically reviewed.
-
Yes. Reduced food intake, lower fibre intake and dehydration may contribute. Fluids, vegetables, fruit, fibre and physical activity may help, although fibre should be increased gradually.
Seek medical advice for severe pain, vomiting or prolonged constipation.
-
The medication helps regulate appetite and metabolic pathways while it is being used, but it does not permanently remove the biological tendency toward weight regain. Long-term habits and an appropriate maintenance strategy remain important.
Ready to Take the First Step?
Book a consultation at Emberwood Aesthetics, Wheelock Place, for an individual assessment and doctor-supervised weight-management plan.
Prescription medication is supplied only after medical consultation and when clinically appropriate. Treatment outcomes and side effects vary between individuals. This information is educational and does not replace personalised medical advice.